Sökning: onr:"swepub:oai:lup.lub.lu.se:323b67c4-a505-45cf-ad4e-48df40436b20" >
Empirical estimates...
-
Vickers, Andrew J.
(författare)
Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen
- Artikel/kapitelEngelska2014
Förlag, utgivningsår, omfång ...
-
2014-02-11
-
Springer Science and Business Media LLC,2014
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:lup.lub.lu.se:323b67c4-a505-45cf-ad4e-48df40436b20
-
https://lup.lub.lu.se/record/4439428URI
-
https://doi.org/10.1186/1741-7015-12-26DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:art swepub-publicationtype
-
Ämneskategori:ref swepub-contenttype
Anmärkningar
-
Background: Prostate cancer screening depends on a careful balance of benefits, in terms of reduced prostate cancer mortality, and harms, in terms of overdiagnosis and overtreatment. We aimed to estimate the effect on overdiagnosis of restricting prostate specific antigen (PSA) testing by age and baseline PSA. Methods: Estimates of the effects of age on overdiagnosis were based on population based incidence data from the US Surveillance, Epidemiology and End Results database. To investigate the relationship between PSA and overdiagnosis, we used two separate cohorts subject to PSA testing in clinical trials (n = 1,577 and n = 1,197) and a population-based cohort of Swedish men not subject to PSA-screening followed for 25 years (n = 1,162). Results: If PSA testing had been restricted to younger men, the number of excess cases associated with the introduction of PSA in the US would have been reduced by 85%, 68% and 42% for age cut-offs of 60, 65 and 70, respectively. The risk that a man with screen-detected cancer at age 60 would not subsequently lead to prostate cancer morbidity or mortality decreased exponentially as PSA approached conventional biopsy thresholds. For PSAs below 1 ng/ml, the risk of a positive biopsy is 65 (95% CI 18.2, 72.9) times greater than subsequent prostate cancer mortality. Conclusions: Prostate cancer overdiagnosis has a strong relationship to age and PSA level. Restricting screening in men over 60 to those with PSA above median (>1 ng/ml) and screening men over 70 only in selected circumstances would importantly reduce overdiagnosis and change the ratio of benefits to harms of PSA-screening.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Sjoberg, Daniel D.
(författare)
-
Ulmert, DavidLund University,Lunds universitet,Urologi, Malmö (Abrahamsson),Forskargrupper vid Lunds universitet,Klinisk kemi, Malmö,Urological research, Malmö,Lund University Research Groups,Clinical Chemistry, Malmö(Swepub:lu)klke-dul
(författare)
-
Vertosick, Emily
(författare)
-
Roobol, Monique J.
(författare)
-
Thompson, Ian
(författare)
-
Heijnsdijk, Eveline A. M.
(författare)
-
De Koning, Harry
(författare)
-
Atoria-Swartz, Coral
(författare)
-
Scardino, Peter T.
(författare)
-
Lilja, HansLund University,Lunds universitet,Klinisk kemi, Malmö,Forskargrupper vid Lunds universitet,Clinical Chemistry, Malmö,Lund University Research Groups(Swepub:lu)klke-hli
(författare)
-
Urologi, Malmö (Abrahamsson)Forskargrupper vid Lunds universitet
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:BMC Medicine: Springer Science and Business Media LLC121741-7015
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Vickers, Andrew ...
-
Sjoberg, Daniel ...
-
Ulmert, David
-
Vertosick, Emily
-
Roobol, Monique ...
-
Thompson, Ian
-
visa fler...
-
Heijnsdijk, Evel ...
-
De Koning, Harry
-
Atoria-Swartz, C ...
-
Scardino, Peter ...
-
Lilja, Hans
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Medicinska och f ...
-
och Läkemedelskemi
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Urologi och njur ...
- Artiklar i publikationen
-
BMC Medicine
- Av lärosätet
-
Lunds universitet